Starpharma secures FDA backing as DEP HER2 moves toward first human trial

The Melbourne-based biotechnology company confirmed that a recent Type C meeting with the regulator received positive feedback on both the proposed phase 1 trial design and the broader clinical strategy for DEP HER2, a dendrimer-based radioligand therapy for difficult-to-treat cancers. …